Stockscreener 앱 받기
0.6769
3.73%
-0.0262
시간 외 거래:
.68
0.0031
+0.46%
전일 마감가:
$0.7031
열려 있는:
$0.709
하루 거래량:
112.89K
Relative Volume:
0.24
시가총액:
$16.21M
수익:
$49.59M
순이익/손실:
$-15.61M
주가수익비율:
-0.1182
EPS:
-5.7281
순현금흐름:
$-32.55M
1주 성능:
-7.65%
1개월 성능:
-13.48%
6개월 성능:
-0.46%
1년 성능:
-41.14%
1일 변동 폭
$0.67
$0.709
1주일 범위
$0.67
$0.7933
52주 변동 폭
$0.4677
$1.65
Cosmos Health Inc Stock (COSM) Company Profile
명칭
Cosmos Health Inc
전화
312-536-3102
주소
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Cosmos Health Inc 주식(COSM)의 최신 뉴스
Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21% - Big News Network
CosmoFarm reports 8.62% revenue increase in 2024 By Investing.com - Investing.com Canada
CosmoFarm reports 8.62% revenue increase in 2024 - Investing.com India
Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with - PharmiWeb.com
Cosmos Health’s Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21% - StockTitan
Cointreau Is Shaking Up Holiday Entertaining with Limited-Edition Cointreau, Cosmos + Caviar Kit - Yahoo Finance
Cosmos Health (NASDAQ:COSM) versus Sinopharm Group (OTCMKTS:SHTDF) Financial Contrast - Defense World
Head to Head Survey: Cosmos Health (NASDAQ:COSM) and Sinopharm Group (OTCMKTS:SHTDY) - Defense World
Cosmos Healthcare Introduces Neuromap® and QPAN Model: AI-Driven Personalized Care for Autism & Neurological - EIN News
Virax Biolabs Group Limited Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland - Marketscreener.com
Contrasting Sinopharm Group (OTCMKTS:SHTDF) & Cosmos Health (NASDAQ:COSM) - Defense World
Analyzing McKesson Europe (OTCMKTS:CAKFY) and Cosmos Health (NASDAQ:COSM) - Defense World
Pre-market Movers: ALZN, VRAX, APDN, LQDA... - RTTNews
An Epic Dystopia - The American Prospect
Cosmos Health (NASDAQ:COSM) vs. ScripsAmerica (OTCMKTS:SCRCQ) Critical Contrast - Defense World
Taking the lead: Cosmos Health Inc (COSM) - SETE News
Evaluating COSM’s financial ratios for a profitable investment - US Post News
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands - AccessWire
Company’s Banking Shares: Up -50.73% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Investor’s Delight: Cosmos Health Inc (COSM) Closes Weak at 1.01, Down -8.18 - The Dwinnex
Cosmo First expects plastic business to turn profitable by the fourth quarter this year - CNBCTV18
Cosmos Health secures UK orders for antimicrobial wash By Investing.com - Investing.com Australia
Recovery room: Skye, Corbus mend post-Novo CB1 weight-loss data - BioWorld Online
Cosmos Health secures UK orders for antimicrobial wash - Investing.com
Cosmos Health signs deal for mpox detection kits in India - Investing.com India
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins - Lelezard
Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits - Lelezard
Core Scientific (NASDAQ:CORZ) Coverage Initiated at Canaccord Genuity Group - Defense World
Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development - Newsfile
Cosmos Health begins development of new GI disorder treatment By Investing.com - Investing.com Australia
Railway stock hits 5% upper circuit after receiving order worth ₹ 127.4 Cr for steel sheet piles - Trade Brains
Here's why this multibagger railway wagon stock hit 5% upper circuit on September 20 - Moneycontrol
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
Cosmos Health begins development of new GI disorder treatment - Investing.com
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion - Big News Network
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastroin - PharmiWeb.com
FY2024 EPS Estimates for Cosmos Health Inc. (NASDAQ:COSM) Reduced by Taglich Brothers - Defense World
COSMCosmos Holdings Inc. Latest Stock News & Market Updates - StockTitan
Cosmos Health Inc. Expected to Earn Q1 2025 Earnings of ($0.07) Per Share (NASDAQ:COSM) - Defense World
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments - AccessWire
Positive Ascendis data threatens BioMarin's lead in achondroplasia - The Pharma Letter
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price - AccessWire
Cosmos Health to distribute mpox PCR kits across GCC, including Qatar - Doha News
Virax Biolabs expands Mpox test kit distribution in GCC By Investing.com - Investing.com Canada
Virax Biolabs expands Mpox test kit distribution in GCC - Investing.com
Cosmos Health expands mpox kit distribution to Gulf States - Investing.com
Cosmos Health Inc (COSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
2.60%
자본화:
|
볼륨(24시간):